Heme-dependent and independent soluble guanylate cyclase activators and vasodilation

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Since the discovery of nitric oxide (NO), which is released from endothelial cells as the main mediator of vasodilation, its target, the soluble guanylyl cyclase (sGC), has become a focus of interest for the treatment of diseases associated with endothelial dysfunction. NO donors were developed to suppress NO deficiency; however, tolerance to organic nitrates was reported. Non-NO-based drugs targeting sGC were developed to overcome the problem of tolerance. In this review, we briefly describe the process of sGC activation by its main physiological activator NO and the advances in the development of drugs capable of activating sGC in a NO-independent manner. sGC stimulators, as some of these drugs are called, require the integrity of the reduced heme moiety of the prosthetic group within the sGC and therefore are called heme-dependent stimulators. Other drugs are able to activate sGC independent of heme moiety and are hence called heme-independent activators. Because pathologic conditions modulate sGC and oxidize the heme moiety, the heme-independent sGC activators could potentially become drugs of choice because of their higher affinity to the oxidized enzyme. However, these drugs are still undergoing clinical trials and are not available for clinical use.

Original languageEnglish (US)
Pages (from-to)229-233
Number of pages5
JournalJournal of Cardiovascular Pharmacology
Volume56
Issue number3
DOIs
StatePublished - Sep 1 2010

Fingerprint

Heme
Vasodilation
Nitric Oxide
Pharmaceutical Preparations
Soluble Guanylyl Cyclase
Nitric Oxide Donors
Drug Delivery Systems
Nitrates
Oxides
Endothelial Cells
Clinical Trials
Enzymes

Keywords

  • endothelial dysfunction
  • nitric oxide
  • soluble guanylyl cyclase activators
  • vascular disease
  • vascular smooth muscle

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. / Priviero, Fernanda; Webb, R Clinton.

In: Journal of Cardiovascular Pharmacology, Vol. 56, No. 3, 01.09.2010, p. 229-233.

Research output: Contribution to journalReview article

@article{32370e3b5e964413bfd31156bc4be6c6,
title = "Heme-dependent and independent soluble guanylate cyclase activators and vasodilation",
abstract = "Since the discovery of nitric oxide (NO), which is released from endothelial cells as the main mediator of vasodilation, its target, the soluble guanylyl cyclase (sGC), has become a focus of interest for the treatment of diseases associated with endothelial dysfunction. NO donors were developed to suppress NO deficiency; however, tolerance to organic nitrates was reported. Non-NO-based drugs targeting sGC were developed to overcome the problem of tolerance. In this review, we briefly describe the process of sGC activation by its main physiological activator NO and the advances in the development of drugs capable of activating sGC in a NO-independent manner. sGC stimulators, as some of these drugs are called, require the integrity of the reduced heme moiety of the prosthetic group within the sGC and therefore are called heme-dependent stimulators. Other drugs are able to activate sGC independent of heme moiety and are hence called heme-independent activators. Because pathologic conditions modulate sGC and oxidize the heme moiety, the heme-independent sGC activators could potentially become drugs of choice because of their higher affinity to the oxidized enzyme. However, these drugs are still undergoing clinical trials and are not available for clinical use.",
keywords = "endothelial dysfunction, nitric oxide, soluble guanylyl cyclase activators, vascular disease, vascular smooth muscle",
author = "Fernanda Priviero and Webb, {R Clinton}",
year = "2010",
month = "9",
day = "1",
doi = "10.1097/FJC.0b013e3181eb4e75",
language = "English (US)",
volume = "56",
pages = "229--233",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Heme-dependent and independent soluble guanylate cyclase activators and vasodilation

AU - Priviero, Fernanda

AU - Webb, R Clinton

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Since the discovery of nitric oxide (NO), which is released from endothelial cells as the main mediator of vasodilation, its target, the soluble guanylyl cyclase (sGC), has become a focus of interest for the treatment of diseases associated with endothelial dysfunction. NO donors were developed to suppress NO deficiency; however, tolerance to organic nitrates was reported. Non-NO-based drugs targeting sGC were developed to overcome the problem of tolerance. In this review, we briefly describe the process of sGC activation by its main physiological activator NO and the advances in the development of drugs capable of activating sGC in a NO-independent manner. sGC stimulators, as some of these drugs are called, require the integrity of the reduced heme moiety of the prosthetic group within the sGC and therefore are called heme-dependent stimulators. Other drugs are able to activate sGC independent of heme moiety and are hence called heme-independent activators. Because pathologic conditions modulate sGC and oxidize the heme moiety, the heme-independent sGC activators could potentially become drugs of choice because of their higher affinity to the oxidized enzyme. However, these drugs are still undergoing clinical trials and are not available for clinical use.

AB - Since the discovery of nitric oxide (NO), which is released from endothelial cells as the main mediator of vasodilation, its target, the soluble guanylyl cyclase (sGC), has become a focus of interest for the treatment of diseases associated with endothelial dysfunction. NO donors were developed to suppress NO deficiency; however, tolerance to organic nitrates was reported. Non-NO-based drugs targeting sGC were developed to overcome the problem of tolerance. In this review, we briefly describe the process of sGC activation by its main physiological activator NO and the advances in the development of drugs capable of activating sGC in a NO-independent manner. sGC stimulators, as some of these drugs are called, require the integrity of the reduced heme moiety of the prosthetic group within the sGC and therefore are called heme-dependent stimulators. Other drugs are able to activate sGC independent of heme moiety and are hence called heme-independent activators. Because pathologic conditions modulate sGC and oxidize the heme moiety, the heme-independent sGC activators could potentially become drugs of choice because of their higher affinity to the oxidized enzyme. However, these drugs are still undergoing clinical trials and are not available for clinical use.

KW - endothelial dysfunction

KW - nitric oxide

KW - soluble guanylyl cyclase activators

KW - vascular disease

KW - vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=77957562992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957562992&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e3181eb4e75

DO - 10.1097/FJC.0b013e3181eb4e75

M3 - Review article

C2 - 20571429

AN - SCOPUS:77957562992

VL - 56

SP - 229

EP - 233

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -